Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III multi-center, double-blind, placebo-controlled, parallel group 24-week study to assess the efficacy and safety of two dose regimens of liquid certolizumab pegol [Cimzia] as additional medication to methotrexate in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate.

Next Previous
X
Search
Trial Profile

A phase III multi-center, double-blind, placebo-controlled, parallel group 24-week study to assess the efficacy and safety of two dose regimens of liquid certolizumab pegol [Cimzia] as additional medication to methotrexate in the treatment of signs and symptoms of rheumatoid arthritis and in prevention of joint damage in patients with active rheumatoid arthritis who have an incomplete response to methotrexate.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Certolizumab pegol (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms RAPID-2
  • Sponsors UCB

    • Most Recent Events

    • 04 Jun 2020 According to an UCB media release, post-hoc analysis results from the pooled studies RAPID 1 (NCT00152386), RAPID 2 (NCT00175877), J-RAPID (NCT00791999) and RAPID-C (NCT02151851) were presented at the Annual European Congress of Rheumatology (EULAR) 2020.
    • 10 May 2011 Results from a post hoc analysis of this trial (RAPID-2) have been published in the Annals of Rheumatic Diseases according to a UCB media release; results were also reported in the media release.
    • 17 Mar 2011 Secondary endpoint results published in the Annals of the Rheumatic Diseases.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top